NVO - Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk Eli Lilly On Safety Concerns | Benzinga
Australia announced on Wednesday that it would ban compounded versions of weight-loss drugs like Novo Nordisk A/S’s (NYSE:NVO) Ozempic and Eli Lilly And Co’s (NYSE:LLY) Mounjaro, citing safety concerns.
Recently, the Chinese regulatory authority approved Eli Lilly’s diabetes drug, tirzepatide.
Health Minister Mark Butler emphasized that these unregulated copies have not undergone rigorous testing, leading to potential patient risks.
Related: The Ozempic Diet: Nestle Launches $5 Pizza For Weight Loss Drug Users.
Demand for Ozempic and Mounjaro has surged due to their effectiveness in weight loss. However, the ...